MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-06-30, APDN had -$1,690,960 decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$1,690,960

Unit: Dollar
Cash Flow
2025-06-30
Stock-based compensation
80,373
Change in provision for bad debts
5,423
Prepaid expenses, other current assets and deposits
-417,738
Inventories
-94,002
Accounts receivable
-33,782
Accounts payable and accrued liabilities
-172,657
Net loss from continuing operations
-9,585,822
Depreciation and amortization
255,601
Loss on write-off of property and equipment
5,212
Unrealized gain on change in fair value of warrants classified as a liability
318,840
Deferred revenue
43,500
Net cash used in operating activities from continuing operations
-9,141,688
Purchase of property and equipment
313,121
Net cash used in investing activities from continuing operations
-313,121
Net proceeds from exercise of warrants
2,215,828
Net proceeds from issuance of common stock and pre-funded warrants
5,712,700
Net cash provided by financing activities from continuing operations
7,928,528
Cash used in operating activities
-185,679
Cash provided by investing activities
21,000
Net cash used by discontinued operations
-164,679
Net (decrease) increase in cash, cash equivalents and restricted cash
-1,690,960
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

APPLIED DNA SCIENCES INC (APDN)

APPLIED DNA SCIENCES INC (APDN)